Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2007 May;66(5):628-32.
doi: 10.1136/ard.2006.062554. Epub 2006 Dec 14.

Clinical trial of a leucotriene B4 receptor antagonist, BIIL 284, in patients with rheumatoid arthritis

Federico Díaz-González  1 , Rieke H E Alten, William G Bensen, Jacques P Brown, John T Sibley, Maxime Dougados, Stefano Bombardieri, Patrick Durez, Pablo Ortiz, Gonzalo de-Miquel, Alexander Staab, Ralf Sigmund, Laurence Salin, Caroline Leledy, Stephen H Polmar
Affiliations
Randomized Controlled Trial

Clinical trial of a leucotriene B4 receptor antagonist, BIIL 284, in patients with rheumatoid arthritis

Federico Díaz-González et al. Ann Rheum Dis. 2007 May.

Abstract

Background: Several clinical and experimental lines of evidence suggest that leucotriene B4 (LTB4), an arachidonic acid derivative with potent proinflammatory properties, plays a key role in the pathophysiology of rheumatoid arthritis (RA).

Objective: To evaluate the efficacy and safety of BIIL 284, an oral long-acting LTB4 receptor antagonist, as monotherapy for the treatment of patients with active RA.

Methods: This was a multi-centre, randomised, double-blind, placebo-controlled trial of patients with active RA of 3 months' duration. A total of 342 patients were randomised to receive 5 mg, 25 mg or 75 mg of BIIL 284 or placebo. The primary end point was the percentage of patients achieving an American College of Rheumatology (ACR) 20.

Results: Although a higher percentage of ACR 20 responders was observed in the groups treated with 25 mg and 75 mg of BIIL 284 compared with those treated with placebo, no statistically significant differences were found between any of the three active treatment groups compared with the placebo group with regard to the primary or secondary end points. All trial treatments were safe and well tolerated.

Conclusions: This clinical trial demonstrates that treatment of patients with active RA with a potent oral long-acting LTB4 receptor antagonist produced only modest improvements in disease activity. The results of this trial support the conclusion that LTB4 is not a major contributor to the inflammatory process in RA.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

References

    1. Henderson W R., Jr The role of leukotrienes in inflammation. Ann Intern Med 1994121684–697. - PubMed
    1. Ford‐Hutchinson A W. Leukotriene B4 in inflammation. Crit Rev Immunol 1990101–12. - PubMed
    1. Lewis R A, Austen K F, Soberman R J. Leukotrienes and other products of the 5‐lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. N Engl J Med 1990323645–655. - PubMed
    1. Leppert D, Hauser S L, Kishiyama J L, An S, Zeng L, Goetzl E J. Stimulation of matrix metalloproteinase‐dependent migration of T cells by eicosanoids. FASEB J 199591473–1481. - PubMed
    1. Yokomizo T, Izumi T, Chang K, Takuwa Y, Shimizu T. A G‐protein‐coupled receptor for leukotriene B4 that mediates chemotaxis. Nature 1997387620–624. - PubMed

Publication types